AirMid Critical Care Products, Inc.

Our patented devices can prevent acute lung injury in 190,000 patients, including more than 72,000 deaths a year as a result of inadvertent lung overinflation

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Washington D.C., DC, USA
  • Currency USD
  • Founded January 2017
  • Employees 2
  • Incorporation Type C-corp
  • Website N

Company Summary

AirMid's volume controlled manual ventilators aim to replace an FDA "grandfathered" and unimproved 1950’s technology resuscitation-bag, which contributes to causing acute lung injury (ACI) in 190,000 patients each year. Inadvertent overinflation of the lungs results in more than 72,000 deaths a year, and creates $20B in downstream cost of care. The predicate device's U.S. market is <$1.5B.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free